[{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":1.03,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus BioSciences","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus BioSciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Humanized IgG2 Agonistic Monoclonal Antibody","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus BioSciences"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Junshi Biosciences"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"LBL-007","moa":"LAG3 pathway","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0.77000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.77000000000000002,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biolabs \/ BeiGene"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Pharmakon Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"JS006","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"HMPL-453","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CHS-006","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD73","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Onatasertib","moa":"TORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Icatolimab","moa":"BTLA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Junshi","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Junshi"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GFH018","moa":"TGF beta-1","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Toripalimab","moa":"IgG2","graph1":"Oncology","graph2":"Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ ISU ABXIS","highestDevelopmentStatusID":"8","companyTruncated":"Eucure Biopharma \/ ISU ABXIS"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Rxilient Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Rxilient Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Rxilient Biotech"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"ADG126","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Suzhou Limited \/ Exelixis"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0.72999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.72999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Leads Biolabs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"LBL-007","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Leads Biolabs","highestDevelopmentStatusID":"7","companyTruncated":"Chime Biologics \/ Leads Biolabs"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tifcemalimab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"INO-3112","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coherus Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pharmaceuticals \/ Coherus Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Biosciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"9MW2821","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Cancer Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"ENB003","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Cancer Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Coherus Biosciences \/ Cancer Research Institute"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"TopAlliance Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ TopAlliance Biosciences"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Junshi Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Toripalimab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
